Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by carduon Jul 11, 2011 4:43pm

387 Views

Post# 18819718

Going forward

For the life of me I can't see any positive news ahead for the rest of the year, hopefully someone can correct me on that statement. The Amsterdam presentation was, to say the least, a non-event if you compare it to the hype I read on both boards prior to its release. Now I hear there is a problem in recruiting for the Phase 3 trial.

What this company needs now, IMO, is a partner who has an experienced and tested PR department. If not, expect the SP to wander downwards for the rest of the year. Dejavu.

Bullboard Posts

Thunder Gold makes generational discovery